INTRODUCTION
============

Cognitive impairments are one of the common neurocognitive abnormalities in schizophrenia \[[@b1-pi-2018-07-22],[@b2-pi-2018-07-22]\]. The deficits involve a number of cognitive domains such as general intelligence, attention, working memory, verbal fluency, verbal learning and memory as well as executive functioning \[[@b3-pi-2018-07-22]\]. These cognitive domains are assessed using several neuropsychological testing batteries. Trail Making Test (TMT) is commonly used to assess motor processing speed, complex visual scanning and cognitive flexibility \[[@b4-pi-2018-07-22]\]. TMT-A, which is used to evaluate processing speed, requires the participant to connect the serially numbers that are scattered on a page by drawing a line. Meanwhile, TMT-B is done by alternately linking the sequentially numbers and letters on a page. This will provide information on cognitive flexibility of the individual \[[@b5-pi-2018-07-22]\].

Cognitive impairment in schizophrenia patients can be associated with several factors such as age \[[@b6-pi-2018-07-22]\], gender \[[@b7-pi-2018-07-22]\]. education duration, illness duration \[[@b8-pi-2018-07-22]\], age of onset and negative symptoms \[[@b9-pi-2018-07-22]\]. However, the effects of these factors on cognitive domains are inconclusive \[[@b10-pi-2018-07-22]-[@b13-pi-2018-07-22]\]. TMT is highly sensitive to attentional and executive impairments, as well as to psychomotor slowing. It is proven that the TMT performance is affected by age, education and intelligence \[[@b14-pi-2018-07-22],[@b15-pi-2018-07-22]\], where age and education were significantly correlated with TMT-A and TMT-B scores \[[@b4-pi-2018-07-22]\]. Although substance-abusing schizophrenia patients had worse clinical outcomes compared to non-substance abusing patients \[[@b16-pi-2018-07-22]\], a study demonstrated that schizophrenia patients with substance abuse showed substantially better performance in executive functions measured by TMT-A and B \[[@b17-pi-2018-07-22]\]. On the other hand, several studies showed no significant difference in executive functions between these two groups of patients \[[@b18-pi-2018-07-22],[@b19-pi-2018-07-22]\].

As cognitive impairment has been proposed as putative endophenotypes in schizophrenia \[[@b20-pi-2018-07-22],[@b21-pi-2018-07-22]\], investigation of factors that may affect the cognitive performance is essential. Thus, the current study aimed to conduct a meta-analysis on cognitive processing speed as well as cognitive flexibility of schizophrenia patients based on TMT-A and TMT-B scores, respectively. Our study also investigated the association of substance abuse, education duration, illness duration and patients' clinical status with their cognitive performance.

METHODS
=======

Literature search
-----------------

Two databases, PsycARTICLES and PubMed, were searched with these keywords: "trail making test," "schizophrenia patients," and "controlled studies." The search included articles related to human subjects published from 1985 until November 2017 and was not subjected to English-language restriction. At the first stage of screening, a total of 263 studies was identified, including 242 papers from PsycARTICLES and 21 papers from PubMed. Then, non-related articles, such as literature reviews, meta-analysis, interviews, systematic reviews and mathematical model papers were filtered. This led to the retrieval of 32 eligible articles for full-text review ([Figure 1](#f1-pi-2018-07-22){ref-type="fig"}).

Criteria for inclusion
----------------------

All the selected articles selected met the following criteria. First, all the patients included in this analysis must be diagnosed within the schizophrenia spectrum i.e. schizophrenia, schizoaffective disorder and schizophreniform disorder, based on the Diagnostic and Statistical Manual of Mental Disorders (DSM) and International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) criteria. Second, the data for TMT-A and TMT-B must be presented as separated values and completed with mean, standard deviation and total sample number. Third, for randomized trials and pilot studies, only baseline scores were included in the analysis. For this, due to the present of two TMT values in a single article, the article was cited with the addition of 'a' and 'b' letter in the parentheses at the end of author's name. Thus, from the 32 retrieved articles, only 19 of those met the inclusion criteria.

Data collection and description of the studies
----------------------------------------------

First authors' names, year of publication, characteristics of participants as well as the mean and standard deviation values of TMT (TMT-A and B) were extracted from each paper ([Table 1](#t1-pi-2018-07-22){ref-type="table"}). Two types of analyses were conducted: 1) comparison between the TMT scores of schizophrenia patients and healthy controls and 2) mean of each of the TMT scores among the patients. Subgroup analyses were performed in order to study the association between cognitive performance of patients and their duration of education, duration of illness as well as their hospital status as inpatients or outpatients. The mean age of the cases ranged between 23.0 years to 43.0 years for patients and 23.8 years to 42.0 years for controls. Meanwhile, the mean education and duration of illness of the patients ranged from 10.0 years to 12.8 years and 1.0 year to 18.2 years, respectively. In terms of drug history, the patients in all but 2 studies were medicated at the time of assessment. In general, the patients from different studies had received one or combination of these therapies: antipsychotic drugs, antidepressant, antiparkinsonian, minor tranquilizers and mood stabilizers.

Data analysis
-------------

The cognitive functional areas assessed by TMT-A and TMT-B are the psychomotor processing speed and cognitive flexibility, respectively. All analyses were performed using Comprehensive Meta-Analysis (CMA) version 2 (Biostat, Englewood, NJ, USA). Depending on the Q statistic value, either the fixed or random effects model were adopted to calculate the effect sizes (ESs) and 95% confidence. In this study, the ESs were analyzed as standardized difference in means (SMDs). Then, the SMDs of TMT data was used to determine the probability of superiority (PS) \[[@b40-pi-2018-07-22]\]. The mean time for TMT-A and B completions were compared to the standard. The standard average time to complete TMT-A and B are 29 seconds and 75 seconds, respectively. However, the cognitive functioning was considered deficit if the time to complete TMT-A and B exceeds 78 seconds and 273 seconds, respectively. If the heterogeneity was considered non-trivial, a random effects model was applied in the meta-analysis. Otherwise, a fixed effects model would be utilized. The heterogeneity between studies was quantified using I-squared (I^2^) and tau-squared (τ^2^) \[[@b41-pi-2018-07-22]\]. I^2^ describes the percentage of observed variance across studies which caused by heterogeneity rather than chance \[[@b42-pi-2018-07-22]\]. The magnitude of heterogeneity is divided into 3 levels, which are low (I^2^≤25%), moderate (25%\< I^2^≤50%) and high (I^2^\>50%). Meanwhile, τ^2^ indicates the actual variance between-studies in the random effects model. Subgroup analyses based on the presence or absence of substance abuse disorder, patients' clinical status (inpatient or outpatient), the duration of their education and illness were conducted in the presence of heterogeneity. The difference in the mean completion time for each subgroups was examined using the Student's t-test with SPSS 14.0 software (SPSS Inc., Chicago, IL, USA) with the significant differences at p\<0.050.

RESULTS
=======

Psychomotor processing speed
----------------------------

Four case-control studies for a total of 441 subjects were included in this analysis. The comparison between 273 schizophrenia patients and 168 healthy controls generated SMD=-0.89 \[random effect, 95% CI (-1.35, -0.42), Z=-3.729, p=0.000\] with I^2^=78% and PS=0.74 ([Figure 2](#f2-pi-2018-07-22){ref-type="fig"}). These results demonstrated that there was a significant reduction in psychomotor processing speed among patients with schizophrenia with a high probability (74%) to identify a schizophrenia patient suffering deficit in processing speed compared to healthy controls. However, there was a significantly (p=0.003) high heterogeneity between the studies of which 78% of the observed variance might be caused by the actual difference in the effect size rather than random error.

To determine the mean for completion of TMT-A among the schizophrenia patients, 827 patients were included in the analysis ([Figure 3](#f3-pi-2018-07-22){ref-type="fig"}). The calculated mean was 51.05 \[random effect, 95% CI (46.64, 55.46), Z=22.700, p=0.000\] with I^2^=88%. Nevertheless, the heterogeneity test showed a significant (p=0.000) dispersion across the effect size. Thus, subgroup analyses were performed. All analyses showed that substance abuse, education and clinical status and duration of illness caused insignificant (p\>0.050) differences on the mean of TMT-A completion time ([Table 2](#t2-pi-2018-07-22){ref-type="table"}). We also found that the drug naïve patients in the study of Huang et al. \[[@b38-pi-2018-07-22]\] spent longer time (7.08 seconds) than overall patients in completing TMT-A test.

Executive function (cognitive flexibility)
------------------------------------------

A total of 7 case-control studies were included in this analysis. The SMD for the comparison between 457 schizophrenia patients and 309 healthy controls was -0.96 \[95% CI (-1.23, -0.70)\] and this value was statistically significant (random effect, Z=-7.095, p=0.000) with I^2^= 64% and PS= 0.75, indicating that patients' cognitive flexibility was impaired ([Figure 4](#f4-pi-2018-07-22){ref-type="fig"}).

Meanwhile, the mean for overall patients' TMT-B was 126.28 \[random effect, 95% CI (105.69, 146.87), Z=12.021, p=0.000\] with I^2^= 98% ([Figure 5](#f5-pi-2018-07-22){ref-type="fig"}). Due to the high magnitude of heterogeneity between studies, subgroup analyses were conducted ([Table 3](#t3-pi-2018-07-22){ref-type="table"}). However, all the differences in the mean completion time obtained from subgroup analyses for TMT-B were insignificant (p\>0.050). However, the completion time for drug naïve patients \[[@b38-pi-2018-07-22]\] was 11.97 seconds faster than the overall patients.

DISCUSSION
==========

As supported by other studies \[[@b43-pi-2018-07-22]-[@b45-pi-2018-07-22]\], current meta-analysis study demonstrated that psychomotor processing speed and cognitive flexibility of schizophrenia patients were significantly impaired compared to the healthy controls. In addition, meta-analysis of TMT-A and B scores obtained from drug naïve schizophrenia patients also demonstrated that they performed worse than the healthy controls \[[@b46-pi-2018-07-22]\]. Based on the calculated mean time of completion of TMT-A and B in the current study, we can conclude that patients' cognitive performances were below average but did not fall in the deficit category. Cognitive dysfunction in schizophrenia patients may caused by genetic and socio-demographic factors \[[@b47-pi-2018-07-22]-[@b51-pi-2018-07-22]\].

Cognitive performances in schizophrenia has been associated with the synchronization of neuronal activity in prefrontal cortex and hippocampus \[[@b52-pi-2018-07-22]\]. Cognitive flexibility is controlled by dopaminergic, serotonergic and cholinergic systems \[[@b53-pi-2018-07-22]\]. Interaction of serotonergic system with other neurotransmitter systems mediates modulatory effects on cognitive performances \[[@b54-pi-2018-07-22]\]. Drug abuse can be a risk factor of schizophrenia manifestation or as a consequence of the underlying schizophrenia neuropathology. Drugs abuse and cognitive impairments in schizophrenia might be attributed to the shared mechanisms \[[@b55-pi-2018-07-22]\]. Due to the antipsychotic medications, the dopamine (DA) neurotransmission will be interfered as a result of the D2 receptor blockade in nucleus accumbens and ventral pallidum, leading to anhedonia \[[@b55-pi-2018-07-22]\]. Consequently, in order to compensate the induced anhedonia, patients may seek for drug abuse which leads to the aggravation of negative symptoms and cognitive deficits \[[@b55-pi-2018-07-22]\]. In addition, even in individual without schizophrenia manifestation, drug intoxication from the use of cocaine, methamphetamine and marijuana can cause psychotic episodes as a result of excess DA in nucleus accumbens and striatal as well as DA deficit in prefrontal cortex \[[@b54-pi-2018-07-22]\]. Contradictory to previous findings \[[@b56-pi-2018-07-22],[@b57-pi-2018-07-22]\], our study showed that there was no effect of concurrent drug abuse on the patients' cognitive performances. However, after the subdivision, the I^2^ and τ^2^ values were reduced compared with the overall analysis for each TMT. Nevertheless, the τ^2^ values for the substance abuse subgroup remained high, due to the inclusion of mixed group of patients in the subgroup analysis of substance abuse. Approximately 73% of the patients were concurrent substance abuser. Thus, the overall score for both tasks might not fully reflect their cognitive performance.

Years of formal schooling will reflect the pre-morbid functioning, intellectual level and higher level of information-processing skills in patients \[[@b13-pi-2018-07-22]\]. It has been demonstrated that longer duration of formal education will give positive impact on several cognitive domains such as vigilance, executive function, memory and constructional ability \[[@b13-pi-2018-07-22]\]. Although we did not find significant effect of duration of education on both cognitive domains, our results are suggestive of the idea that education affects executive function more strongly than processing speed.

In addition, hospitalization will also affect the cognitive functions of schizophrenia patients. As shown by the results from analysis of TMT-B, outpatients without concurrent substance abuse performed better than inpatients. This observation complements previous findings \[[@b58-pi-2018-07-22]\], which indicated a correlation between hospitalization and cognitive regression development. Additionally, delirium, treatment, anxiety and depression during hospitalization could be potential contributors to the relationship between hospitalization and cognitive decline.

Last but not least, we found that duration of illness had only a small effect on cognitive performances of the patients. Patients with longer duration of illness exhibited only slightly larger means of TMT completion time. Another study also demonstrated that cognitive impairment began at the illness onset and remained stable throughout the illness course \[[@b8-pi-2018-07-22]\]. Moreover, Srinivasan and colleagues found that most of the neuropsychological batteries used to measure cognitive functions in schizophrenia were stable over a range periods of illness \[[@b13-pi-2018-07-22]\].

Our study has several limitations. We were unable to investigate the correlation between schizophrenia subtypes or spectrums and patient's processing speed as well as cognitive flexibility due to the lack of studies concerning these subjects. In addition, we could not compare the TMT scores between medicated and drug naive patients. We could only compare the mean of overall data for each TMT test with the results for drug naïve patients obtained by Huang et al. \[[@b38-pi-2018-07-22]\] Our comparison showed that drug naïve patients had slower performance to complete TMT-A but better performance in TMT-B. This is because treatment with typical and/or atypical antipsychotics might have an impact on TMT scores. This is because, typical antipsychotics usually antagonize D2 receptors due to their high affinity towards the receptors \[[@b59-pi-2018-07-22]\] while most atypical antipsychotics block either only D2 receptors or concurrently antagonize HTR2A and D2 receptors \[[@b60-pi-2018-07-22]\]. The blocking of D2 receptors, especially by typical antipsychotics may lead to Parkinsonian side effects and tardive dyskenia, as a result of the drug accumulation in the brain tissue \[[@b61-pi-2018-07-22]\]. This in turns may lead to difficulty for the patients to complete the TMT as this test is highly reflected by motor rigidity.

In conclusion, the current meta-analysis study indicated that the cognitive function of schizophrenia patients measured by TMT-A and B were impaired compared to healthy controls. Substance abuse, patients' clinical status, duration of education as well as illness showed only small effects on the tasks' scores. These findings demonstrated that the studied variables may not affect the patients' TMT scores greatly.

![Study ascertainment diagram. TMT-A: Trail Making Test A, TMT-B: Trail Making Test B.](pi-2018-07-22f1){#f1-pi-2018-07-22}

![Measures of cognitive processing speed using TMT-A. Horizontal lines represent 95% confidence interval (CI). The diamond represents the point estimate for the effect size. The vertical line represents the reference of no difference in means between the schizophrenia (Scz) group and healthy control (HC) group. df: degree of freedom, PS: probability of superiority, std diff: standardized difference, τ^2^ : tausquared. TMT-A: Trail Making Test A.](pi-2018-07-22f2){#f2-pi-2018-07-22}

![Means of TMT-A completion time for all schizophrenia patients. Horizontal lines represent 95% confidence interval (CI). The diamond represents the point estimate for the mean effect size. The vertical lines represent the standard reference of mean for normal (black line) and deficient (gray line) cognitive performance. df: degree of freedom, τ^2^ : tau-squared. TMT-A: Trail Making Test A.](pi-2018-07-22f3){#f3-pi-2018-07-22}

![Measure of cognitive flexibility using TMT-B. Horizontal lines represent 95% confidence interval (CI). The diamond represents the point estimate for the effect size. The vertical line represents the reference of no difference in means between the schizophrenia (Scz) group and healthy control (HC) group. df: degree of freedom, std diff: standardized difference, τ^2^ : tau-squared. TMT-B: Trail Making Test B.](pi-2018-07-22f4){#f4-pi-2018-07-22}

![Means of TMT-B completion time for schizophrenia patients only. Horizontal lines represent 95% confidence interval (CI). The diamond represents the point estimate for the mean effect size. The vertical lines represent the standard reference of mean for normal (black line) and deficient (gray line) cognitive performance. df: degree of freedom, τ^2^ : tau-squared. TMT-B: Trail Making Test B.](pi-2018-07-22f5){#f5-pi-2018-07-22}

###### 

Characteristics of studies included in the present meta-analysis

  Authors                                            TMT-A(N)                            TMT-B(N)   Mean age (years)   \% Male   Patients status                   Education (years)       Duration of illness (years)         Psychopathological evaluation       Patients medication                                                    Schizophrenia spectrum diagnosis                                            Substance abused
  -------------------------------------------------- ----------------------------------- ---------- ------------------ --------- --------------------------------- ----------------------- ----------------------------------- ----------------------------------- ---------------------------------------------------------------------- --------------------------------------------------------------------------- ------------------
  Katsanis and Iacono \[[@b22-pi-2018-07-22]\]       65 Scz                              65 Scz     28.15              87        Inpatients                        NA                      9.51                                BPRS: 33.53                         62 Scz on antipsychotics                                               65 Chronic schizophrenia                                                    No
  GAF: 36.74                                         44 Scz on AP agents                                                                                                                                                                                                                                                                                                                                              
  NSI: 5.33                                          4 Scz on lithium carbonate                                                                                                                                                                                                                                                                                                                                       
  PSI: 6.93                                          4 Scz on AD                                                                                                                                                                                                                                                                                                                                                      
  12 Scz on minor tranquilizers                                                                                                                                                                                                                                                                                                                                                                                       
  Goldberg et al. \[[@b23-pi-2018-07-22]\]           NA                                  57 Scz     34.00              53        Inpatients                        NA                      11.1                                BPRS                                13 Scz on antipsychotics                                               57 Schizophrenia                                                            No
  Positive symptoms: 21.1                            15 Scz on antipsychotics and AD                                                                                                                                                                                                                                                                                                                                  
  Negative symptoms: 9.2                             1 Scz on lithium                                                                                                                                                                                                                                                                                                                                                 
  11 Scz on lithium and antipsychotics                                                                                                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                               3 Scz on AD                                                                                                                                                                            
                                                                                                                                                                                                                               1 Scz on others                                                                                                                                                                        
                                                                                                                                                                                                                               3 Scz drug naive                                                                                                                                                                       
  Lapierre et al. \[[@b24-pi-2018-07-22]\]           31 Scz                              31 Scz     36.00              100       Outpatients                       10                      NA                                  PANSSP: 13                          All Scz on several psychiatric medications                             31 Schizophrenia                                                            Yes (16/31)
  PANSSN: 14                                                                                                                                                                                                                                                                                                                                                                                                          
  15 HC                                              15 HC                               33.87      67                           19.17                             None                                                                                                                                                                                                                                               
  Docherty et al. \[[@b25-pi-2018-07-22]\]           NA                                  26 Scz     32.00              80        Outpatients                       13                      10                                  GAF: 53                             All Scz on antipsychotics                                              26 Stable schizophrenia                                                     No
  8 Scz on typical antipsychotics                                                                                                                                                                                                                                                                                                                                                                                     
  18 Scz on atypical antipsychotics                                                                                                                                                                                                                                                                                                                                                                                   
  9 Scz on AP agents                                                                                                                                                                                                                                                                                                                                                                                                  
  6 Scz on MS                                                                                                                                                                                                                                                                                                                                                                                                         
  12 Scz on others                                                                                                                                                                                                                                                                                                                                                                                                    
  van der Gaag et al. \[[@b26-pi-2018-07-22]\] (a)   21 Scz                              21 Scz     30.40              62        Inpatients                        Scale: 4.3              9.9                                 NA                                  All on stable antipsychotics                                           21 Schizophrenia                                                            No
  6 Scz on clozapine                                                                                                                                                                                                                                                                                                                                                                                                  
  36 Scz on typical antipsychotics                                                                                                                                                                                                                                                                                                                                                                                    
  van der Gaag et al. \[[@b26-pi-2018-07-22]\] (b)   21 Scz                              21 Scz     31.70              67        Inpatients                        Scale: 4.7              9.6                                 NA                                                                                                         21 Schizophrenia                                                            No
  Martínez-Arán et al. \[[@b27-pi-2018-07-22]\]      49 Scz                              49 Scz     30.40              78        Outpatients                       11.3                    NA                                  GAF: 69.8                           45 Scz on typical antipsychotics                                       49 Schizophrenia                                                            No
  PANSSP: 11.5                                       4 Scz on atypical antipsychotics                                                                                                                                                                                                                                                                                                                                 
  PANSSN: 22.5                                       22 Scz on AD                                                                                                                                                                                                                                                                                                                                                     
  4 Scz on MS                                                                                                                                                                                                                                                                                                                                                                                                         
  Velligan et al. \[[@b28-pi-2018-07-22]\] (a)       15 Scz                              15 Scz     39.33              53        Outpatients                       11.2                    NA                                  BPRS positive: 2.62                 13 Scz on atypical antipsychotics                                      11 Schizophrenia/4 Schizoaffective disorder                                 Yes (2/15)
  NSA total: 72.47                                                                                                                                                                                                                                                                                                                                                                                                    
  Velligan et al. \[[@b28-pi-2018-07-22]\] (b)       15 Scz                              15 Scz     38.93              60        Outpatients                       11.2                    NA                                  BPRS positive: 3.32                 10 Scz on atypical antipsychotics                                      11 Schizophrenia/4 Schizoaffective disorder                                 Yes (2/15)
  NSA total: 70.40                                                                                                                                                                                                                                                                                                                                                                                                    
  Holthausen et al. \[[@b29-pi-2018-07-22]\]         118 Scz                             118 Scz    23.30              74        NA                                Scale: 4                NA                                  PANSSP\*: 2.22                      25 Scz on typical antipsychotics                                       84 Schizophrenia/15 Schizoaffective disorder/19 Schizophreniform disorder   Yes (99/118)
  PANSSN\*: 2.33                                     75 Scz on atypical antipsychotics                                                                                                                                                                                                                                                                                                                                
  45 HC                                              45 HC                               24.00      84                           Scale: 5.4                        None                                                        18 Scz did not use antipsychotics                                                                                                                                                      
                                                     10 Scz on AC                                                                                                                                                                                                                                                                                                                                                     
  Pukrop et al. \[[@b30-pi-2018-07-22]\]             NA                                  66 Scz     30.10              70        Inpatients                        NA                      NA                                  PANSSP: 16.5                        35 Scz unmedicated                                                     61 Paranoid/2 Disorganized/3 Undifferentiated schizophrenia                 No
  PANSSN: 20.1                                       4 Scz on typical antipsychotic                                                                                                                                                                                                                                                                                                                                   
  NA                                                 45 HC                               29.60      31                           NA                                None                                                        27 Scz on atypical antipsychotics                                                                                                                                                      
  Combs and Qouvier \[[@b31-pi-2018-07-22]\]         65 Scz                              65 Scz     40.7               55        NA                                11.2                    18.2                                BPRS: 53.8                          15 Scz on typical antipsychotics                                       65 Chronic schizophrenia                                                    No
  34 Scz on atypical antipsychotics                                                                                                                                                                                                                                                                                                                                                                                   
  16 Scz on both antipsychotics                                                                                                                                                                                                                                                                                                                                                                                       
  36 Scz on AC agents                                                                                                                                                                                                                                                                                                                                                                                                 
  Herman \[[@b17-pi-2018-07-22]\] (a)                35 Scz                              35 Scz     42.17              N.a.      Inpatients                        10.9                    NA                                  BPRS: 55.55                         12 Scz on typical antipsychotics                                       35 Schizophrenia                                                            No
  32 Scz on atypical antipsychotics                                                                                                                                                                                                                                                                                                                                                                                   
  Herman \[[@b17-pi-2018-07-22]\] (b)                44 Scz                              43 Scz     30.86              N.a.      Inpatients                        11.26                   NA                                  BPRS: 45.60                         13 Scz on typical antipsychotics                                       44 Schizophrenia                                                            Yes (44/44)
  33 Scz on atypical antipsychotics                                                                                                                                                                                                                                                                                                                                                                                   
  Docherty \[[@b32-pi-2018-07-22]\]                  47 Scz                              47 Scz     43.00              83        Inpatients                        13                      NA                                  BPRS: 49                            NA                                                                     47 Schizophrenia                                                            No
  GAF: 42                                                                                                                                                                                                                                                                                                                                                                                                             
  36 HC                                              36 HC                               42.00      39                           14                                None                                                                                                                                                                                                                                               
  Keri et al. \[[@b33-pi-2018-07-22]\]               NA                                  72 Scz     NA                 65        Outpatients                       N.a.                    NA                                  BPRS: 30.4                          20 Scz on typical antipsychotics                                       72 Schizophrenia                                                            No
  NA                                                 60 HC                               NA         67                           N.a.                              None                    51 Scz on atypical antipsychotics                                                                                                                                                                                          
  Mortimer et al. \[[@b34-pi-2018-07-22]\] (a)       9 Scz                               8 Scz      N.a.               NA        NA                                NA                      NA                                  BPRS: 30.8 (N=ll)                   Patients on antipsychotics, AD, AC and/or benzodiazepine medications   (N=NA) Schizophrenia/Schizophreniform disorder                              NA
  Predominant positive symptomatology                                                                                                                                                                                                                                                                                                                                                                                 
  Mortimer et al. \[[@b34-pi-2018-07-22]\] (b)       14Scz                               14 Scz     N.a.               NA        NA                                NA                      NA                                  BPRS score: 35.3 (N=16)                                                                                    (N=NA) Schizophrenia/S chizophreniform disorder                             NA
  Predominant positive symptomatology                                                                                                                                                                                                                                                                                                                                                                                 
  Thornton et al. \[[@b35-pi-2018-07-22]\]           48 Scz                              47 Scz     35.90              64        Inpatients                        11.4                    14.5                                NA                                  44 Scz on antipsychotic medication                                     39 Schizophrenia/11 Schizoaffective disorder                                No
  Yi et al. \[[@b36-pi-2018-07-22]\] (a)             9 Scz                               9 Scz      41.40              78        Outpatients                       12.3                    NA                                  PANSSP: 14.4                        Patients on antipsychotics                                             (N=NA) Schizophrenia/Schizoaffective disorder                               No
  PANSSN: 14.6                                                                                                                                                                                                                                                                                                                                                                                                        
  Yi et al. \[[@b36-pi-2018-07-22]\] (b)             10 Scz                              10 Scz     39.70              70        Outpatients                       12.8                    NA                                  PANSSP: 13.9                        Patients on antipsychotics                                             (N=NA) Schizophrenia/Schizoaffective disorder                               No
  PANSSN: 17.5                                                                                                                                                                                                                                                                                                                                                                                                        
  Hasan et al. \[[@b37-pi-2018-07-22]\] (a)          73 Scz                              71 Scz     36.40              86        Inpatients and outpatients        11.5                    NA                                  PANSSP: 14.2 (N=67)                 Patients on stable antipsychotics                                      73 schizophrenia                                                            No
  PANSSN: 25.6 (N=68)                                                                                                                                                                                                                                                                                                                                                                                                 
  Hasan et al. \[[@b37-pi-2018-07-22]\] (b)          78 Scz                              76 Scz     35.50              72        Inpatients and outpatients        11.2                    NA                                  PANSSP: 13.0 (N=71)                 Patients on stable antipsychotics                                      78 schizophrenia                                                            No
  PANSSN: 25.2 (N=74)                                                                                                                                                                                                                                                                                                                                                                                                 
  Huang et al. \[[@b38-pi-2018-07-22]\]              92 Scz                              92 Scz     22.86              39        NA                                10.77                   12.26                               PANSSP: 23.88                       Drug naive                                                             92 first-episode schizophrenia                                              NA
  PANSSN: 19.30                                                                                                                                                                                                                                                                                                                                                                                                       
  57 HC                                              57 HC                               23.84      42                           11.77                             None                                                                                                                                                                                                                                               
  Schuepbach et al. \[[@b39-pi-2018-07-22]\]         15 Scz                              15 Scz     33.20              67        10 inpatients and 5 outpatients   12.77                   10.43                               BPRS: 36.53                         Patients on antipsychotics                                             15 chronic schizophrenia                                                    No
  15 HC                                              15 HC                               33.87      67                 19.17     None                              4 Scz on AD and/or MS                                                                                                                                                                                                                              

standardized PANSS ratings ranging from 1 (absent) to 7 (extreme).

AC: anticholinergic, AD: antidepressant, AP: antiparkinsonian, BPRS: Brief Psychiatric Rating Scale, GAF: Global Assessment of Functioning, HC: healthy controls, MS: mood stabilizers, N: total number, NA: not available, NSI: Negative Symptom Index, PANSSN: Positive and Negative Syndrome Scale-Negative, PANSSP: Positive and Negative Syndrome Scale-Positive, PSI: Positive Symptom Index, Scz: schizophrenia patients

###### 

Summary of subgroup analyses for TMT-A in schizophrenia patients

  Subgroups                                                        Mean and 95% CI          p-value   Sample size   τ^2^     *I*^2^ (%)   Q-value   df (Q)
  ---------------------------------------------------------------- ------------------------ --------- ------------- -------- ------------ --------- ------------------------------------------------------
  Concurrent substance abuse                                                                                                                        
   a. Absent                                                       48.02 \[43.08, 52.97\]   0.112     489           59.86    86           76.24     11^[\*\*](#tfn3-pi-2018-07-22){ref-type="table-fn"}^
   b. Present                                                      58.94 \[36.83, 81.05\]             223           127.69   90           41.94     4^[\*\*](#tfn3-pi-2018-07-22){ref-type="table-fn"}^
  Education (without concurrent substance abuse)                                                                                                    
   a. 12 years and below                                           47.14 \[39.40, 54.89\]   0.482     348           85.09    92           68.27     5^[\*\*](#tfn3-pi-2018-07-22){ref-type="table-fn"}^
   b. More than 12 years                                           50.87 \[43.91, 57.84\]             34            38.85    50           4.02      4
  Patients' clinical status (without concurrent substance abuse)                                                                                    
   a. Inpatients                                                   47.89 \[42.38, 52.59\]   0.301     190           21.21    66           11.88     4^[\*](#tfn2-pi-2018-07-22){ref-type="table-fn"}^
   b. Outpatients                                                  51.31 \[45.21, 57.41\]             68            20.15    38           3.25      2
  Duration of illness                                                                                                                               
   a. 10 years and below                                           50.07 \[43.92, 56.22\]   0.872     199           24.18    64           8.24      2^[\*](#tfn2-pi-2018-07-22){ref-type="table-fn"}^
   b. More than 10 years                                           49.35 \[35.35, 63.35\]             128           139.41   94           31.20     2^[\*\*](#tfn3-pi-2018-07-22){ref-type="table-fn"}^

p\<0.050,

p\<0.001.

CI: confidence interval, df: degree of freedom, τ2: tau-squared, TMT-A: Trail Making Test A

###### 

Summary of schizophrenia patients' subgroup analyses for TMT-B

  Subgroups                                                        Mean and 95% CI            p-value   Sample size   τ^2^       *I*^2^ (%)   Q-value   df (Q)
  ---------------------------------------------------------------- -------------------------- --------- ------------- ---------- ------------ --------- ------------------------------------------------------
  Concurrent substance abuse                                                                                                                            
   a. Absent                                                       123.08 \[103.99,142.18\]   0.779     710           492.67     90           138.76    14^[\*\*](#tfn4-pi-2018-07-22){ref-type="table-fn"}^
   b. Present                                                      127.63 \[57.45,197.81\]              222           6,114.36   97           149.64    4^[\*\*](#tfn4-pi-2018-07-22){ref-type="table-fn"}^
  Education (without concurrent substance abuse)                                                                                                        
   a. 12 years and below                                           132.01 \[102.47,161.55\]   0.675     343           1,258.86   95           101.66    5^[\*\*](#tfn4-pi-2018-07-22){ref-type="table-fn"}^
   b. More than 12 years                                           121.38 \[94.95,147.81\]              107           755.77     85           27.08     4^[\*\*](#tfn4-pi-2018-07-22){ref-type="table-fn"}^
  Patients' clinical status (without concurrent substance abuse)                                                                                        
   a. Inpatients                                                   140.41 \[91.83,188.98\]    0.29      317           1,101.09   93           76.49     5^[\*\*](#tfn4-pi-2018-07-22){ref-type="table-fn"}^
   b. Outpatients                                                  116.22 \[100.26,132.18\]             166           46.34      32           5.92      4
  Duration of illness                                                                                                                                   
   a. 10 years and below                                           114.22 \[104.61,123.82\]   0.686     183           85.9       0            0.095     2
   b. More than 10 years                                           118.59 \[96.44,140.75\]              184           448.41     88           25.26     3^[\*\*](#tfn4-pi-2018-07-22){ref-type="table-fn"}^

p\<0.001.

CI: confidence interval, df: degree of freedom, τ^2^: tau-squared, TMT-B: Trail Making Test B
